Weight Loss Medications We Prescribe At the forefront of weight management in Walnut Creek, California, Klinic offers a selection of FDA-approved branded weight loss medications, tailored to your needs
In the two-year SUSTAIN 6 trial, semaglutide significantly reduced the risk of the occurrence of a three-component MACE endpoint consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke
![is ozempic stronger than semaglutide Zepbound the Same as Ozempic? Key Differences Explained [2026] Is Ozempic (Semaglutide) Lower the](https://c.ndtvimg.com/2023-08/n3bsndno_ozempic-drug-afp-1200_625x300_03_August_23.jpg?im=FeatureCrop,algorithm=dnn,width=640,height=360,output=(format=webp,quality=90))
Semaglutide Quick Facts: Drug Class: GLP-1 receptor agonist Brand Names: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral) FDA Approval: Ozempic approved 2017, Wegovy approved 2021 Manufacturer: Novo Nordisk Dosing: Once weekly injection, starting at 0.25 mg, maximum 2.4 mg Clinical Trial Name: STEP trials (Semaglutide Treatment Effect in People with obesity) Average Weight Loss: 10-15% of body weight over 68 weeks Tirzepatide Quick Facts: Drug Class: Dual GIP/GLP-1 receptor agonist Brand Names: Mounjaro (diabetes), Zepbound (weight loss) FDA Approval: Mounjaro approved 2022, Zepbound approved 2023 Manufacturer: Eli Lilly Dosing: Once weekly injection, starting at 2.5 mg, maximum 15 mg Clinical Trial Name: SURMOUNT trials (Study to evaluate tirzepatide in obesity or overweight) Average Weight Loss: 15-22% of body weight over 72 weeks Primary Difference: The main distinction is that semaglutide activates only GLP-1 receptors, while tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
![is ozempic stronger than semaglutide Zepbound the Same as Ozempic? Key Differences Explained [2026] Is Ozempic (Semaglutide) Lower the](https://assets.clevelandclinic.org/transform/71c7b21b-3a27-4549-bc68-a02945c5a825/wegovy-versus-ozempic-infographic?io=transform:fit,width:780)
Bupropion-naltrexone (Contrave) Contrave combines an antidepressant (bupropion) with an opioid antagonist (naltrexone) to target reward-based eating behaviors
BPI Labs operates out of Largo, Florida as both an FDA-registered drug manufacturer and a 503B outsourcing facility
Its design includes a fatty acid side chain (C-18 fatty di-acid) that allows it to bind to albumin in the blood, extending its half-life